Comparison of efficacy between intralesional bleomycin and cryotherapy in plantar warts
DOI:
https://doi.org/10.66344/jpad.v29i1.1200Keywords:
Intralesional, bleomycin, plantar warts, cryotherapyAbstract
Objective To compare the efficacy of intralesional bleomycin and cryotherapy in treating plantar warts.
Material and Methods A total of 160 patients (80 in each group) were enrolled, who were randomly divided into 2 groups. Group A was treated with 0.1% intralesional bleomycin and group B was treated with liquid nitrogen with a cotton swab. Follow-up was carried out at 02, 04 and 06 weeks and the final efficacy was calculated at the end of 06 weeks.
Results Out of 160 patients, 32 (40.0%) male and 48 (60.0%) female were enrolled in intralesional bleomycin group; 30(36.5%) male and 50 (62.5%) females were included in cryotherapy group. Mean±SD of age in intralesional bleomycin and cryotherapy was 28.24±4.2 with C.I (27.30-29.17) and 27.56±3.8 with C.I (26.71-28.40) years, respectively. In comparison of both groups 90% efficacy was found in intralesional bleomycin group whereas 72.5% in cryotherapy group and p value was found to be highly significant i.e. (P=0.005).
Conclusion Intralesional bleomycin is more effective than cryotherapy in the treatment plantar warts.
References
1. Lowy DR, Androphy EJ. Warts. In: Freedberg IM, Eisen AZ,Wolf K, Austen KF, Goldsmith LA, Katz SI, eds. Fitzpatrick’s Dermatology in General Medicine. Vol. 4, 6th ed. New York: McGraw-Hill; 2003. p. 2119-30, 2358, 2575-80.
2. Bacelieri R, Johnson SM. Cutaneous wart: An evidence basedapproach to therapy. Am Fam Physician 2005; 72: 647-52.
3. James WD, Berger TG, Elston DM. Viral Diseases. In: James WD,Berger TG, Elston DM, eds. Andrews, disease of skin: Clinical dermatology. 10th ed. Philadelphia: Saunders Elsevier; 2006. p. 403-15.
4. Haribhakti PB, Macwan R. Viral skin infections. In: Valia RG,Valia AR, eds. IADVL Textbook and Atlas of Dermatology. 2nd ed. Mumbai: Bhalani Publishing House; 2001. p. 303-9.
5. Sterling JC. Virus infections. In: Burns T, Breathnach S, CoxN, Griffiths C, eds.Rook’s Textbook of Dermatology. Vol. 27thed. Massachuesttes: Blackwell Science; 2004. p. 25.39-57.
6. Sterling JC, Handfield-Jones S, Hudson PM. Guidelines for the management of cutaneous warts. Br J Dermatol 2001; 144: 4-11.
7. Ryu HR, Jeong HR, Seon-Woo HS et al. Drug Deliv and Transl Res 2018; 8: 273.
8. Gibbs S, Harvey I, Sterling J, Stark R. Local treatments for cutaneous warts: systematic review. BMJ 2002; 325(7362): 461.
9. Agius E, Mooney JM, Bezzina AC, Yu RC. Dermojet delivery of bleomycin for the treatment of recalcitrant plantar warts. J Dermatol Treat 2006; 17:112-6.
10. Bunney MH, Nolan MW, Buxton PK, Going SM, Prescott RS. The treatment of resistant warts with intralesional bleomycin: A controlled clinical trial. Br J Dermatol 1984; 11:197-207.
11. Munn SE, Higgins E, Marshall M, Clement M. A new method of intralesional bleomycin therapy in the treatment of recalcitrant warts. Br J Dermatol 1996; 135: 969-71.
12. Shelley WB, Shelley ED. Intralesional bleomycin sulfate therapy for warts: A novel bifurcated needle puncture technique. Arch Dermatol 1991; 127: 234-6.
13. Hayes ME, O'keefe EJ. Reduced dose of bleomycin in the treatment of recalcitrant wart. J Am Acad Dermatol 1986; 15: 1002-6.
14. Bourke JF, Berth-Jones J, Hutchinson PE. Cryotherapy of common viral warts at intervals of 1, 2 and 3 weeks. Br J Dermatol 1995; 132: 433-6.
15. Adalatkhah H, Khalilollahi H, Amini N, Sadeghi-Bazargani H. Compared therapeutic efficacy between intralesional bleomycin and cryotherapy for common wart: A randomized clinical trial. Dermatol Online J 2007; 13: 4.
Downloads
Published
Issue
Section
License
Copyright (c) 2019 Jaan Muhammad, Naveed Akhtar, Muhammad Khurram Ahmad, Muhammad Irfan Anwar
This work is licensed under a Creative Commons Attribution 4.0 International License.
Submission declaration
Authors retain the copyright to their work and grant the 'Journal of Pakistan Association of Dermatologists (JPAD)' the right of first publication under a Creative Commons Attribution 4.0 International (CC BY 4.0) license. This license allows others to share, adapt, and reuse the work for any purpose, including commercial use, as long as appropriate credit is given to the original authors and the journal.
By submitting a manuscript, authors confirm that the work has not been published previously (except as an abstract, lecture, or academic thesis), is not under review elsewhere, and has been approved by all authors and relevant authorities. Once accepted, the article will be openly accessible under the CC BY 4.0 license, ensuring wide dissemination and reuse with proper attribution.
